Skip to content
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Search
NYSE American: IGC
Investor Relations
Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
December 13, 2023
Read More →
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
December 6, 2023
Read More →
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
November 21, 2023
Read More →
IGC Pharma Reports Second Quarter Fiscal 2024 Results
November 13, 2023
Read More →
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
October 19, 2023
Read More →
IGC Announces Results of its 2023 Annual Stockholders Meeting
August 21, 2023
Read More →
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials
August 14, 2023
Read More →
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
August 2, 2023
Read More →
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference
July 18, 2023
Read More →
IGC Reports Financial Results for Fiscal Year Ended March 31, 2023
July 12, 2023
Read More →
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer’s Research
July 7, 2023
Read More →
IGC Pharma Announces a $3 Million Private Placement of its Common Stock – Jul 6’23
July 6, 2023
Read More →
IGC Pharma Receives Notice of Allowance for Patent on Seizures – Jun 6’23
June 6, 2023
Read More →
IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award
June 5, 2023
Read More →
IGC Pharma to Present at LD Micro Invitational XIII
May 18, 2023
Read More →
IGC PHARMA to Present at the Planet MicroCap Showcase VEGAS 2023
April 18, 2023
Read More →
